Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
about
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsCytokine-Defined B Cell Responses as Therapeutic Targets in Multiple SclerosisVaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesTeriflunomide in Patients with Relapsing-Remitting Forms of Multiple SclerosisTeriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherenceImmunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Oral disease-modifying therapies for multiple sclerosis.Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Teriflunomide and its mechanism of action in multiple sclerosis.Teriflunomide: a review of its use in relapsing multiple sclerosis.Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.Vaccines in Multiple Sclerosis.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Teriflunomide in multiple sclerosis: an update.Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.Impact of siponimod on vaccination response in a randomized, placebo-controlled study.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Influenza vaccination in patients with multiple sclerosis is possible with some considerations.Immunotherapies and influenza vaccination.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
P2860
Q26770664-5E44FB35-9302-43E5-8238-8A418BAE5302Q26771459-96F660CB-A248-4D81-BCFB-91B663CF91EEQ26796420-85A7F112-D0B8-4837-87CA-C01325BDC15FQ28070118-1D591819-B4C6-4985-AD4F-BD4C6D39D289Q28081876-1BA3365A-3EAE-4C5A-8731-FD6B8A3D0D75Q30357998-35951A72-CD6B-4B82-98B5-03EC455EA6A4Q34389332-4E9982F4-7431-40E0-B4E6-D99552386ECDQ34996562-9F516397-69F3-4A48-AA02-C422EDEF6657Q35105760-36559B9C-1AA3-4E48-B758-5ED187FEFCD9Q37615119-3B6BAB5A-01CF-4CE0-A9E4-DF2EB8F015C0Q37730005-798E855F-BFDA-4444-A458-2280436F5C20Q38160410-88173136-A052-42EF-B0A2-194543742A4BQ38205268-678E7C37-8DF0-4090-A464-7535E7372065Q38289353-9EF99F6D-E89D-438B-90A5-7B69C0A4960CQ38357590-68117BE3-7D0F-4C6D-AA59-A423F274D330Q38752982-5522F972-6DEF-419A-8F97-7B8CF4F23111Q39032639-49F08B34-AFDC-4C6E-B4DB-20D0DF0685DDQ39114065-AFE9DF09-F4DA-490F-93F3-C41C9693EF3AQ40164070-08D686EB-26C0-42F6-8C39-6FA74A0BCA7BQ41686869-8DAA13C5-04E8-4879-A13A-8D7465229949Q41877062-F6C04C45-300D-4DAA-8648-0007FD7561E3Q42641313-E6A696A3-8B07-4177-9116-4E13F796A141Q43317730-31CBAD4F-9F5D-4C53-82F5-2D12D856AC7AQ45066717-CDB4536C-5172-411D-8713-C80E16AC343EQ47105088-B0E1FBEF-FEF3-4753-88C4-1BCCFA77DCDCQ54626497-C1D53871-75EC-4D6E-859D-0AA43D304FEC
P2860
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@en
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@nl
type
label
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@en
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@nl
prefLabel
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@en
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@nl
P2093
P2860
P1433
P1476
Teriflunomide effect on immune ...... ients with multiple sclerosis.
@en
P2093
Amit Bar-Or
Deborah Bauer
Françoise Menguy-Vacheron
Marcelo Kremenchutzky
Mark S Freedman
Myriam Benamor
Paul W O'Connor
Philippe Truffinet
Scott Chambers
Stefan Jodl
P2860
P304
P356
10.1212/WNL.0B013E31829E6FBF
P407
P577
2013-07-12T00:00:00Z